Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

Marcus, Thank you!!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 77
Posts 11,109
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
georgejjl   Friday, 03/15/19 11:05:03 PM
Re: marcusl2 post# 726
Post # of 749 
Marcus, Thank you!!!

Quote:
On to the second deal with Axovant around our Parkinsons' drug OXB-102, now known as AXO-Lenti-PD. It's a worldwide licensing agreement here. Headline value of the deal was $842.5 million. The $30 million upfront here, $55 million was specified development milestones, and a further $757.5 million was specified regulatory and sales milestones. So on the drug here, the royalties we get are higher than we'd normally get in a partnership deal. We get tiered 7% to 10% on sales.

In March 2019, Axovant reported their data from the first cohort of the Phase 1/2 trial and are now planning to move into the second cohort of treatment in the second quarter. Very exciting in this, we're so excited where it can go.

Products in Parkinson's in 2016 sold $3.1 billion, set to rise on our forecast to about $8.8 billion by 2026. It's a huge market we are involved.



https://seekingalpha.com/article/4248943-oxford-biomedicas-oxbdf-ceo-john-dawson-q4-2018-results-earnings-call-transcript?part=single

Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist